ANX-M1 (Human IgG1)
Based on 1 Customer Validation
ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1].
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: ≥99.0%
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 kappa
Human/Mouse
|
C1q |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (adult, postnatal day 60-90, equal numbers of male and female, photo-oxidative damage-induced retinal degeneration)[1]
-
Dosage:7.5 μg/μL (intravitreal post-treatment); 7.5 μg/μL (intravitreal pre-treatment); 100 mg/kg (systemic)
-
Administration:intravitreal (single dose on day 7 or day 0); intraperitoneal (days 0,4,8)
-
Result:Significantly reduced TUNEL+ photoreceptor cell death at day 14 compared to IgG control (P < 0.05), significantly increased outer nuclear layer (ONL) thickness (P < 0.05), significantly improved rod a-wave and b-wave electroretinography (ERG) responses (P < 0.05, most pronounced at 1.9 log cd.s/m²), and significantly improved cone ERG responses (P < 0.05) with intravitreal post-treatment; showed no significant differences in TUNEL+ cell count, ONL thickness, IBA1+ cell count, or ERG responses compared to IgG control (P > 0.05) with intravitreal pre-treatment; reduced serum complement hemolytic activity by >50% at day 12 (P < 0.05) but showed no significant differences in TUNEL+ cell count, ONL thickness, IBA1+ cell count, or ERG responses compared to IgG control (P > 0.05) with systemic administration
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
性状 Liquid
-
Color Colorless to light yellow
-
SMILES
[ANX-M1 (Human IgG1)]
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Jiao H, et al. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. Mol Neurodegener. 2018;13(1):45. Published 2018 Aug 20. [Content Brief]
[2]. Gagnon M, et al. Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease. Molecules. 2023;28(13):5206. Published 2023 Jul 4. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
ANX-M1 (Human IgG1) 関連分類
HY-P991886 関連分類
Powered by Bioz
- ANX-M1 (Human IgG1)
- Complement System
- TUNEL+ photoreceptor cell death
- C57BL/6J mice
- C1q inhibitor
- age-related macular degeneration
- intravitreally
- classical complement pathway activation
- blood-brain barrier
- ERG responses
- B6C3-Tg (APPswe/PSEN1dE9) mice
- retinal degeneration
- serum complement hemolytic activity
- B1R/B2R agonist-functionalized TRIOZAN? nanoparticles
- ONL thickness
- Alzheimer’s disease
- C1q
- Alzheimer disease
- mouse
- photo-oxidative damage
- TRIOZAN? NPs
- anti-C1q monoclonal antibody
- Inhibitor
- inhibitor
- inhibit